Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: cbio), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.Crescent Biopharma, Inc. received a Schedule 13G disclosing that Tang Capital entities and Kevin Tang together hold 700,000 ordinary shares, representing 5.04% of the outstanding class based on 13,892,562 shares. The filing breaks ownership across Tang Capital Management, LLC, Tang Capital Partners, LP (393,681 shares, 2.84%), Tang Capital Partners International, LP (306,319 shares, 2.20%), and Kevin Tang, with shared voting and dispositive power over the full position. The statement affirms the position was not acquired to change or influence control.